Large multinational pharma companies publicly express concern about the threat from China's biopharma sector. Simultaneously, these same companies are investing billions, actively integrating China into the global ecosystem and contradicting their own zero-sum game narrative.

A disconnect exists between the public rhetoric of U.S. pharma leaders, who frame China's growing biotech sector as a threat, and their corporate actions. These same companies are investing heavily in Chinese R&D and manufacturing, revealing a dual strategy of public caution and private commitment to integrating China into the global biopharma ecosystem.

The US biotech industry is divided on collaborating with Chinese firms. A significant group feels trapped in a prisoner's dilemma: they would prefer if everyone stopped working with Chinese companies, but feel forced to engage because if their competitors do, they'll be at a significant disadvantage by opting out.

Beyond innovation or speed, the key structural advantage for the U.S. biotech ecosystem is its deep, unparalleled capital market. This financial moat makes it difficult for Chinese firms to access the scale of funding needed to truly dominate the global landscape.

Driven by significant government investment, China is rapidly becoming a leader in biotech R&D, licensing, and outsourcing. This shift is a top-of-mind concern for US biotech and pharma executives, with China now involved in a majority of top R&D licensing deals.

Beyond just pharma, China is engaging in a 'salami slicing' strategy to take over the foundational infrastructure of the U.S. biotech economy. This slow, incremental acquisition of manufacturing and research capabilities mirrors its successful long-term strategy for dominating sectors like rare earths.

The industry's negative perception of FDA leadership and regulatory inconsistency is having tangible consequences beyond investment chilling. Respondents report actively moving clinical trials outside the U.S. and abandoning vaccine programs. This self-inflicted wound directly weakens America's biotech ecosystem at the precise moment its race with China is intensifying.

John Crowley, CEO of Bio, argues the best strategy for US biotech dominance is not protectionism. Instead, the focus should be on improving the US's own competitive advantages, like streamlining regulations and lowering innovation costs, to maintain its lead rather than trying to stifle Chinese research.

The narrative of China as an innovation 'threat' in biopharma may be a deliberate strategy to spur action in the U.S. By creating a sense of urgency and competition, reminiscent of the U.S.-Soviet superpower struggle, the industry may be attempting to mobilize investment and political will, even if the framing is seen as unfortunate.